Lusutrombopag after stem cell transplant
Part of Blood & lymphatic clinical trials.
This trial tests a medicine called lusutrombopag to help raise low platelet counts after a stem cell transplant from a half-matched family donor. It may be a good option for people who are recovering from transplant and need help with their blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a stem cell transplant from a half-matched family donor (haploidentical).
- You are generally well enough to be up and about (ECOG score 0-2).
- Your doctor expects you to live at least 3 more months.
- Your major organs (heart, liver, kidneys, etc.) are working fairly well.
- You can take pills by mouth and are not allergic to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug hetrombopag can safely raise platelet counts in people with immune thrombocytopenia (ITP) before they have surgery. The goal is to reduce bleeding risk during and after the operation.
This trial tests a drug called avatrombopag (a pill) to help raise platelet counts in people who develop very low platelets after a stem cell transplant from a half-matched donor (haplo-HSCT). It aims to see if the drug is safe and effective at reducing the need for platelet transfusions.
This trial studies whether avatrombopag can help your platelet count recover after a bone marrow transplant from an unrelated donor (UCBT) in certain bone marrow failure diseases. If platelets recover better, it may reduce risks related to low platelets after transplant.
This trial tests two medications (lusutrombopag and recombinant human thrombopoietin) given together to raise platelet levels before a planned surgery in people with chronic liver disease. The goal is to reduce the need for platelet transfusions and make the procedure safer.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
This Phase 2 study tests eltrombopag to improve collection of peripheral blood stem cells in adults with Hodgkin or non-Hodgkin lymphoma. If you’re getting a planned chemotherapy mobilization (like ESHAP, with or without an antibody), this trial may see whether eltrombopag can help your body collect the needed stem cells for transplant or further treatment.
Hear when a new Hematologic Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.